Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TGM1 | P22735 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1896919 | 0.91 | ALDH1A1 (0.49) | ALDH1A1MAPTHPGDF13A1TGM2 | |
| SCHEMBL7367495 | 0.90 | ALDH1A1 (0.58) | ALDH1A1MAPTHPGDF13A1TGM2 | |
| SCHEMBL31626045 | 0.89 | CCR6 (0.49) | ALDH1A1MAPTHPGDF13A1TGM2 | |
| SCHEMBL27267384 | 0.88 | CCR6 (0.48) | ALDH1A1MAPTHPGDF13A1TGM2 | |
| SCHEMBL31697957 | 0.85 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDF13A1TGM2 | |
| SCHEMBL553299 | 0.85 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDF13A1TGM2 | |
| SCHEMBL25978639 | 0.85 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDF13A1TGM2 | |
| SCHEMBL2724661 | 0.85 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDF13A1TGM2 | |
| SCHEMBL13181407 | 0.85 | LTB4R (0.56) | ALDH1A1MAPTHPGDF13A1TGM2 | |
| SCHEMBL25526046 | 0.84 | ALDH1A1 (0.49) | ALDH1A1MAPTHPGDF13A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893256-B2 | Azabicycloalkane compounds | THERAVANCE, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100197922-A1 | AZABICYCLOALKANE COMPOUNDS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7732441-B2 | Azabicycloalkane compounds | THERAVANCE, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1626970-B1 | AZABICYCLOALKANE COMPOUNDS AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080139603-A1 | Azabicycloalkane compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-12 | — | — | US | disclosed |
| US-7358244-B2 | Azabicycloalkane compounds | THERAVANCE, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20040242622-A1 | Azabicycloalkane compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-02 | — | — | US | disclosed |
| EP-0688314-B1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AG (DE) | 2001-10-04 | — | — | EP | disclosed |
| US-5804559-A | WATER SOLUBILITY | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-09-08 | — | — | US | disclosed |
| EP-0688314-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994021604-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-09-29 | — | — | WO | disclosed |
| US-3992437-A | Polyhydrophenanthrene derivatives | STERLING DRUG INC. (US) | 1976-11-16 | — | — | US | disclosed |
| US-3932482-A | CARDIOTONIC | STERLING DRUG INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139603-A1 | Azabicycloalkane compounds | ADRB1, ADRB2, ADRA2B | ALDH1A1 901/4885MAPT 3636/4885HPGD 2880/4885 |
| US-20040242622-A1 | Azabicycloalkane compounds | ADRB1, ADRB2, ADRA1B | ALDH1A1 638/4885MAPT 4287/4885HPGD 2943/4885 |
| US-20100197922-A1 | AZABICYCLOALKANE COMPOUNDS | ADRB1, ADRB2, ADRA2B | ALDH1A1 901/4885MAPT 3636/4885HPGD 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.